OncoMatch/Pancreatic Cancer (PDAC)/KRAS

Pancreatic Cancer (PDAC)KRAS Clinical Trials

44 recruiting trials·Updated daily from ClinicalTrials.gov

KRAS mutations — predominantly G12D (~40%), G12V (~30%), and G12R (~15%) — are present in over 90% of pancreatic ductal adenocarcinomas and represent the most promising emerging target in PDAC. KRAS G12D inhibitors (MRTX1133 and others) and pan-KRAS inhibitors are in active early-phase trials with initial clinical signals. Trials also explore KRAS-targeted combination strategies including SHP2 inhibitors, MEK inhibitors, and immunotherapy.

Match trials to my profile Clinician mode →

Top recruiting

Top recruiting KRAS Pancreatic Cancer (PDAC) trials

Ranked by phase and US site count.

See all trials matched to your profile →

Phase 37 US sites

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Astellas Pharma Global Development, Inc.

Phase 36 US sites

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Revolution Medicines, Inc.

Phase 1/Phase 221 US sites

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Revolution Medicines, Inc.

Phase 1/Phase 216 US sites

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Revolution Medicines, Inc.

Phase 1/Phase 215 US sites

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

Frontier Medicines Corporation

Phase 1/Phase 212 US sites

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Tango Therapeutics, Inc.

Additional trials

More KRAS Pancreatic Cancer (PDAC) trials

See all in search →

Phase 2

NCT07020221A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsPhase 1/Phase 211 US sites NCT07223047A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid MalignanciesPhase 1/Phase 24 US sites NCT07148128Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.Phase 1/Phase 22 US sites NCT06015724Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung CancerPhase 22 US sites NCT04858009Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal MetastasisPhase 21 US site NCT03608631iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D MutationPhase 1/Phase 21 US site NCT06445062Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsPhase 1/Phase 232 US sites NCT06695845A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsPhase 216 US sites NCT03190941Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 PatientsPhase 1/Phase 21 US site

Phase 1

NCT06447662A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.Phase 126 US sites NCT06586515MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid TumorsPhase 125 US sites NCT06026410KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsPhase 120 US sites NCT06218914Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid TumorsPhase 118 US sites NCT06040541Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsPhase 117 US sites NCT06917079BBO-11818 in Adult Subjects With KRAS Mutant CancerPhase 111 US sites

9 international trials (no US sites)

NCT06895031Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASPhase 2 NCT04146298Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic CancerPhase 1/Phase 2 NCT06770452HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer PatientsPhase 2 NCT07353645KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic CancerPhase 1/Phase 2 NCT07483983Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/ResistancePhase 2 NCT05288205Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C MutationPhase 1/Phase 2 NCT06008288A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.Phase 2 NCT07259590A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D MutationPhase 1/Phase 2 NCT06229340Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS MutationsPhase 2

Other Pancreatic Cancer (PDAC) biomarkers

Browse other molecular targets with active Pancreatic Cancer (PDAC) trials.

← All Pancreatic Cancer (PDAC) clinical trials